Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

AstraZeneca

1.373,5

 

SEK

 

-0,15 %

Mindre end 1K følgere

AZN

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
Sammenligne
-0,15%
-1,75%
-15,32%
-5,05%
-6,63%
-16,4%
+6,6%
+34,05%
+7.415,53%

AstraZeneca is a global biopharmaceutical company that focuses on the research, development, and marketing of prescription drugs, primarily for the treatment of diseases in the areas of therapy that affect the respiratory tract, cardiovascular / metabolism, and cancer. In addition to its main operations, the company is also active in autoimmunity, neuroscience, and infection. AstraZeneca is active in all global regions and is headquartered in Cambridge.

Læs mere
Markedsværdi
2,13 bio. SEK
Aktieomsætning
221,92 mio. SEK
Omsætning
596,39 mia.
EBIT %
18,5 %
P/E
27,43
Udbytteafkast, %
2,49 %
Finanskalender
29.7
2025

Delårsrapport Q2'25

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Selskabsmeddelelse28.2.2025, 13.06

AstraZeneca: Enhertu recommended in EU in post-ET breast cancer

AstraZeneca
Selskabsmeddelelse6.2.2025, 07.00

AstraZeneca: Final Results

AstraZeneca
Selskabsmeddelelse7.10.2024, 08.30

AstraZeneca licenses lipid lowering Lp(a) asset

AstraZeneca

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Selskabsmeddelelse7.3.2024, 11.00

AstraZeneca: Notice of AGM

AstraZeneca
Selskabsmeddelelse21.2.2024, 07.00

AstraZeneca: Filing of Form 20-F with SEC

AstraZeneca
Selskabsmeddelelse9.11.2023, 07.00

AstraZeneca: 9M and Q3 2023 results

AstraZeneca
Pressemeddelelse25.7.2022, 06.11

AstraZeneca: Tezspire recommended for approval in the EU by CHMP for the treatment of severe asthma

AstraZeneca
Pressemeddelelse25.7.2022, 06.06

AstraZeneca: Ultomiris recommended for approval in the EU by CHMP for the treatment of adults with generalised myasthenia gravis

AstraZeneca
Pressemeddelelse25.7.2022, 06.01

AstraZeneca: Enhertu granted Priority Review in the US for patients with HER2-low metastatic breast cancer

AstraZeneca
Selskabsmeddelelse19.7.2022, 06.01

AstraZeneca: Enhertu approved in the EU for patients with HER2-positive metastatic breast cancer treated with one or more prior anti-HER2-based regimens

AstraZeneca
Pressemeddelelse16.5.2022, 06.00

AstraZeneca: PT027, a novel fixed-dose combination of albuterol and budesonide, used as an as-needed rescue medicine, significantly reduced the risk of a severe exacerbation

AstraZeneca
Selskabsmeddelelse14.12.2020, 09.00

AstraZeneca to acquire Alexion Pharmaceuticals Inc

AstraZeneca
Selskabsmeddelelse3.12.2019, 09.00

AstraZeneca divests Seroquel rights: US and Canada

AstraZeneca
Selskabsmeddelelse23.10.2018, 09.00

AstraZeneca Extends Innate Pharma Collaboration

AstraZeneca
Selskabsmeddelelse1.10.2018, 09.00

AstraZeneca PLC Announces Agreement with Cheplapharm for rights to Atacand in 28 European countries completed

AstraZeneca
Selskabsmeddelelse24.9.2018, 09.00

Farxiga gets positive result in DECLARE-TIMI 58

AstraZeneca
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team